Perspective Therapeutics, Inc. CATX 深 沪
等待开盘 03-26 09:30:00 美东时间
4.52
+0.230
+5.36%
华盛通- 最 高4.60
- 今 开4.35
- 成交量 89.91万股
- 最 低 4.35
- 昨 收 4.29
- 总市值 5.15亿
- 52周最高 6.16
- 市盈率 静 --
- 换手率 0.79%
- 52周最低 1.60
- 委 比 34.86%
- 总股本 1.14亿
- 历史最高 37.90
- 量 比 0.30
- 振 幅 5.83%
- 历史最低 1.60
- 每 手 1
- 风险率 0.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Data At AACR 2026
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated
03-18 04:47
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
03-17 18:40
Perspective Therapeutics Q4 EPS $(0.51) Misses $(0.36) Estimate, Sales $43.000K Miss $215.615K Estimate.
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.36) by 42.06 percent. This is a 15 percent increase over losses of $(0.60) per share
03-17 04:10
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
Piper Sandler Initiates Coverage On Perspective Therapeutics with Overweight Rating, Announces Price Target of $16
Piper Sandler analyst Biren Amin initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Overweight rating and announces Price Target of $16.
02-19 19:21
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally...
02-18 00:17
